- Home
- PBYI vs NCTY Comparison
PBYI vs NCTY Comparison
Compare PBYI & NCTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- NCTY
- Stock Information
- Founded
- PBYI 2010
- NCTY 1999
- Country
- PBYI United States
- NCTY China
- Employees
- PBYI N/A
- NCTY N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- NCTY Business Services
- Sector
- PBYI Health Care
- NCTY Consumer Discretionary
- Exchange
- PBYI Nasdaq
- NCTY Nasdaq
- Market Cap
- PBYI 171.7M
- NCTY 156.7M
- IPO Year
- PBYI N/A
- NCTY 2004
- Fundamental
- Price
- PBYI $3.28
- NCTY $9.13
- Analyst Decision
- PBYI Strong Buy
- NCTY
- Analyst Count
- PBYI 1
- NCTY 0
- Target Price
- PBYI $7.00
- NCTY N/A
- AVG Volume (30 Days)
- PBYI 351.2K
- NCTY 57.9K
- Earning Date
- PBYI 08-07-2025
- NCTY 01-01-0001
- Dividend Yield
- PBYI N/A
- NCTY N/A
- EPS Growth
- PBYI 143.51
- NCTY N/A
- EPS
- PBYI 0.77
- NCTY N/A
- Revenue
- PBYI $232,709,000.00
- NCTY $15,305,175.00
- Revenue This Year
- PBYI N/A
- NCTY N/A
- Revenue Next Year
- PBYI N/A
- NCTY N/A
- P/E Ratio
- PBYI $4.25
- NCTY N/A
- Revenue Growth
- PBYI 2.68
- NCTY N/A
- 52 Week Low
- PBYI $2.23
- NCTY $5.75
- 52 Week High
- PBYI $4.13
- NCTY $20.59
- Technical
- Relative Strength Index (RSI)
- PBYI 40.98
- NCTY 47.63
- Support Level
- PBYI $3.34
- NCTY $9.13
- Resistance Level
- PBYI $3.55
- NCTY $9.82
- Average True Range (ATR)
- PBYI 0.13
- NCTY 0.63
- MACD
- PBYI -0.02
- NCTY 0.05
- Stochastic Oscillator
- PBYI 11.11
- NCTY 12.33
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.